Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of switching from dual to triple antiretroviral therapy on inflammation in HIV-1 infection
2019-000199-41Phase 4Active
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide, dolutegravir and lamivudine in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS) (2 arms), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Change in plasma sCD14 concentration. Started Jun 2019; status: active.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamidedolutegravirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on 2019-000199-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000199-41.